Freedman Financial Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-10,185
Closed -$519K 298
2022
Q1
$519K Buy
10,185
+638
+7% +$33.1K 0.36% 36
2021
Q4
$564K Sell
9,547
-53
-0.6% -$2.63K 0.39% 33
2021
Q3
$413K Buy
9,600
+106
+1% +$4.7K 0.3% 38
2021
Q2
$372K Sell
9,494
-1,700
-15% -$66.1K 0.28% 40
2021
Q1
$406K Sell
11,194
-300
-3% -$10.7K 0.34% 36
2020
Q4
$423K Buy
+11,494
New +$422K 0.38% 32

Other funds holding PFE

Freedman Financial Associates's PFE Position: Q2 2022 in Review

Freedman Financial Associates sold out of Pfizer (PFE) in Q2 2022, closing a stake of 10,185 shares — an estimated $519K sold.

Freedman Financial Associates first reported a position in PFE in Q4 2020 and held it in 6 quarters. The position peaked at $564K in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

  • Freedman Financial Associates reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 10,185 Pfizer shares in Q2 2022, an estimated $519K.
  • Freedman Financial Associates first reported a position in Pfizer in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's Pfizer position peaked at $564K in Q4 2021.
  • 3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.